| Gilead Sciences, Inc. | Key Financials | Relative to Peer Avg |
|---|---|---|
| Quarterly Revenue Growth | 11.45% | |
| Annual Revenue Growth | 31.34% | |
| Quarterly Net Income Growth | 63.41% | |
| Annual Net Income Growth | -1.03% | |
| Quarterly Free Cash Flow Growth | ||
| Total Debt Relative to Total Capital | 46.48% | |
| Operating Margin | 40.49% | |
| Return on Equity | 28.287% |
| Gilead Sciences, Inc. (GILD) Dilution Analysis | |||
|---|---|---|---|
| Latest EPS | $0.43 | -$0.03 | |
| Company | Revenue* | Net Income* | Rating | Sentiment |
|---|---|---|---|---|
| AMGN | 4,242.00 | 1,434.00 | Sign up to view | |
| GILD | 2,531.17 | 722.19 | Sign up to view | |
| CELG | 1,471.00 | 384.90 | Sign up to view | |
| BIIB | 1,414.00 | 426.75 | Sign up to view | |
| LIFE | 962.51 | 121.20 | Sign up to view | |
| GRFS | 899.94 | 119.78 | Sign up to view | |
| REGN | 439.66 | 98.87 | Sign up to view | |
| ALXN | 333.79 | 82.22 | Sign up to view | |
| ILMN | 330.96 | -22.59 | Sign up to view | |
| VRTX | 328.37 | -308.02 | Sign up to view | |